Follow the Knight Therapeutics Inc. share price and the full directors' dealings record of the company, a publicly traded company based in Canada. Shares trade on CA CA, under the authority of SEDI. Market capitalisation: €962.2m. The latest transaction was disclosed on 15 July 2026 (51 - Exercise of options). Among the most active insiders: Groleau, Melanie. The full history is free.
43
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 18,285 of 28,168 companies
42.3
score / 100
Value
39
Quality
45
FCF yld3.7%
Earn yld-0.6%
EV/EBITDA17.2x
ROE1.9%
Gross mgn44%
Net mgn-1.2%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
5,129 shares@ CA$9.250.0033% mcap4.1% of flowCommon SharesTSXSEDI:4733880
Canonical exit: 8 Sept 2026 (T+90)
25 of 43 declarations
About Knight Therapeutics Inc.
Knight Therapeutics Inc. is a Canadian pharmaceutical company focused on acquiring and developing drugs for the Canadian and international markets. It is listed on the Toronto Stock Exchange under the symbol KNT.